Trimipramine

Depression is a high-burden psychiatric disorder worldwide. As classic clinical medications, tricyclic antidepressants still have an irreplaceable position in the treatment of moderate to severe depression. Trimipramine is a tertiary amine tricyclic antidepressant. Its mechanism of action covers the inhibition of 5-hydroxytryptamine and norepinephrine reuptake, and it also has a strong sedative effect. Clinically, in addition to treating various types of depression, especially in patients with symptoms of anxiety and insomnia, it can also be used for the adjuvant treatment of childhood enuresis and chronic neuropathic pain, with the applicable population covering adults and pediatric patients who meet the indications.

The global market size of tricyclic antidepressants is approximately USD 1.8 billion. Among them, trimipramine, as a segmented variety with relatively mild side effects, has maintained a compound annual growth rate of 2.1% in the past three years, and its main markets are concentrated in Europe, North America and some Asia-Pacific countries. At present, the global market is dominated by generic drug supply, and the market share of the original research product has been less than 10%. There is no approved preparation of this variety in China at present, and the clinical demand is temporarily dependent on import channels, so the overall market is still in an undeveloped stage.

The original research enterprise of trimipramine is Novartis, and the original trade name is Surmontil. Its core compound patent expired globally as early as 1978. The main dosage form approved for the original research product is oral tablet, with specifications including 25mg, 50mg and 100mg, which has been included in the FDA Reference Listed Drug Catalog. Up to now, there is no trimipramine API registration number in the non-for-clinical use, Status I category in China CDE API registration database, and no preparation of this variety has been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for trimipramine API, and most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day, which can meet the rapid verification needs in the R&D stage. Meanwhile, the products meet the compliance requirements of multiple regulations including Chinese Pharmacopoeia and FDA, providing stable and reliable support for pharmaceutical enterprises in impurity research and quality standard establishment.